Tevogen Bio Holdings Inc. (TVGN)
| Market Cap | 43.84M -79.8% |
| Revenue (ttm) | n/a |
| Net Income | -21.94M |
| EPS | -6.48 |
| Shares Out | 4.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100,571 |
| Open | 9.95 |
| Previous Close | 9.86 |
| Day's Range | 9.58 - 10.95 |
| 52-Week Range | 4.14 - 75.50 |
| Beta | 0.16 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 15, 2026 |
About TVGN
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as ... [Read more]
Financial Performance
Financial StatementsNews
Tevogen advances strategic acquisition initiatives
Tevogen (TVGN) announced continued progress across its strategic acquisition initiatives intended to complement its existing business and support long-term financial self-sufficiency, which, if consum...
Tevogen Bio Holdings Inc trading halted, volatility trading pause
11:45 EDT Tevogen (TVGN) Bio Holdings Inc trading halted, volatility trading pause
Tevogen Bio Holdings Inc trading resumes
11:50 EDT Tevogen (TVGN) Bio Holdings Inc trading resumes
Tevogen regains compliance with Nasdaq minimum bid price requirement
Tevogen (TVGN) received written notice from the Nasdaq notifying the company that it had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) for…
Tevogen reports performance advancements for Tevogen.AI platform
Tevogen (TVGN) announced performance advancements for its artificial intelligence platform, operated through Tevogen.AI. Over the past year, the company has built a proprietary database of more than 6...
Tevogen appoints interim leaders across core business verticals
Tevogen (TVGN) announced the appointment of interim leaders across its core business verticals to execute the first phase of its diversified growth strategy. In this first phase, Tevogen is evaluating...
Tevogen CEO says ‘actively evaluating potential acquisitions’
Dr. Ryan Saadi, Founder & CEO Tevogen (TVGN), sent the following letter to shareholders: “Dear Shareholders, As we continue executing on Tevogen’s long-term strategy to evolve into a sustainable, reve...
Tevogen Bio Holdings Inc trading resumes
10:19 EST Tevogen (TVGN) Bio Holdings Inc trading resumes
Tevogen Bio Holdings Inc trading halted, volatility trading pause
10:14 EST Tevogen (TVGN) Bio Holdings Inc trading halted, volatility trading pause
Tevogen Bio Holdings Inc trading halted, news pending
19:50 EST Tevogen (TVGN) Bio Holdings Inc trading halted, news pending
Tevogen signs LOI to evaluate potential acquisition of Apozeal Pharmaceutical
Tevogen (TVGN) announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent to evaluate a potential transaction with Apozeal Pharmaceutical, calling the proposed transactio...
Tevogen downgraded to Hold from Buy at D. Boral Capital
D. Boral Capital downgraded Tevogen (TVGN) to Hold from Buy without a price target citing the company’s 50:1 reverse stock split. While the move is largely technical in nature, reverse…
Tevogen announces 50-for-1 reverse stock split
Tevogen’s (TVGN) Board of Directors has approved a reverse stock split of its common stock at a ratio of 50 for 1. Stockholders previously approved the reverse stock split on…
Tevogen signs LoI to evaluate acquisition of contract research organization
Tevogen (TVGN) announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent to evaluate a potential transaction with a distinguished global contract research organization. ...
Tevogen signs non-binding LOI to evaluate acquisition of Sciometrix
Tevogen (TVGN) has entered into a signed, non-exclusive, non-binding Letter of Intent to evaluate a potential transaction with Sciometrix, a privately held healthcare technology and value-based care s...
Tevogen to evaluate potential one-time special cash dividend
Tevogen (TVGN) announced that its board of directors has expressed its intention to evaluate the potential declaration of a one-time special cash dividend to shareholders, contingent upon the achievem...
Tevogen reports scientific, operational milestones achieved in 2025
Tevogen (TVGN) reported significant scientific and operational milestones achieved in 2025 within its biotechnology operations, reflecting Tevogen’s continued execution toward a scalable, established,...
Tevogen announces clinical milestone in evolution of ExacTcell platform
Tevogen (TVGN) announced a clinical milestone in the evolution of its proprietary ExacTcell platform: completion of T cell target identification for an additional five human leukocyte antigen restrict...
Tevogen provides update on TVGN 489 amid Long COVID patient interest
Tevogen (TVGN) issued an update regarding growing public interest in its investigational precision T cell therapy, TVGN 489, under development for COVID-19 and Long COVID. “We’re deeply moved by the…